title: Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans?
abstract: In animals, high fibroblast growth factor 21 (FGF21) states improve insulin resistance but induce bone loss. Whether FGF21 relates to bone mineral density (BMD) is unknown in humans. Contrary to prediction from animal findings, we found higher FGF21 levels associating with greater BMD in women, independent of age and body composition.
  
  
  BACKGROUND
  Recent laboratory studies suggest that FGF21 is involved in reciprocal regulation of bone and energy homeostasis. Systemic administration of FGF21 protects animals from obesity and diabetes but causes severe bone loss, smothering the enthusiasm over FGF21 as a potential antiobesity therapeutic. To date, there is no information on whether FGF21 relates to BMD in humans. We thus studied the relationship between plasma FGF21 levels and BMD in healthy adults.
  
  
  METHODS
  Fasting plasma FGF21 levels were measured by enzyme-linked immunosorbent assay and body composition by dual-energy X-ray absorptiometry.
  
  
  RESULTS
  Among 40 healthy volunteers (age 32 ± 10 year, 16 women), men had significantly higher lean body mass (p < 0.01) and total BMD (p < 0.05), and lower percent body fat than women (p < 0.01). Median plasma FGF21 levels were not different between the sexes. While there was no association between FGF21 concentrations and body composition in men, FGF21 levels correlated positively with fat mass (p < 0.01) in women. In men, no significant correlation between FGF21 with BMD was observed. However, in women, FGF21 correlated positively with total BMD (R (2) = 0.69, p = 0.003) and spine BMD (R (2) = 0.76, p = 0.001); the correlation remained significant after adjusting for age, ethnicity, and body composition.
  
  
  CONCLUSIONS
  This study reveals for the first time a strong positive association between plasma FGF21 levels and BMD in healthy women, suggesting the association between bone loss and high FGF21 states in animals may not be directly translated to humans in physiologic states. We hypothesize that FGF21 may increase bone mass particularly in women through paracrine mechanisms in the bone-adipose interface.
authors.affiliation: Diabetes, Endocrinology, Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg 10, CRC, 10 Center Drive, Bethesda, MD, USA, pcylee@gmail.com.
authors.forename: P
authors.initials: P
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: Linderman
authors.forename: S
authors.initials: S
authors.lastname: Smith
authors.forename: R J
authors.initials: RJ
authors.lastname: Brychta
authors.forename: R
authors.initials: R
authors.lastname: Perron
authors.forename: C
authors.initials: C
authors.lastname: Idelson
authors.forename: C D
authors.initials: CD
authors.lastname: Werner
authors.forename: K Y
authors.initials: KY
authors.lastname: Chen
authors.forename: F S
authors.initials: FS
authors.lastname: Celi
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D001823:Body Composition / Q000502:physiology; D015519:Bone Density / Q000502:physiology*; D005260:Female; D005346:Fibroblast Growth Factors / Q000097:blood / Q000502:physiology*; D006801:Humans; D008297:Male; D012727:Sex Characteristics; D013131:Spine / Q000502:physiology; D055815:Young Adult
chemical_list: C414620:fibroblast growth factor 21; D005346:Fibroblast Growth Factors
references.citation: Endocrinology. 2007 Feb;148(2):774-81
references.pmid: 17068132
references.citation: PLoS One. 2012;7(12):e51357
references.pmid: 23236485
references.citation: Int J Obes (Lond). 2014 Feb;38(2):170-6
references.pmid: 23736373
references.citation: Curr Diabetes Rev. 2012 Jul 1;8(4):285-93
references.pmid: 22587513
references.citation: Endocr Rev. 2013 Jun;34(3):413-38
references.pmid: 23550082
references.citation: Biochem Biophys Res Commun. 2013 Mar 22;432(4):677-82
references.pmid: 23416071
references.citation: Stem Cells Transl Med. 2012 Dec;1(12):874-85
references.pmid: 23283549
references.citation: Endocrinology. 2008 Dec;149(12):6018-27
references.pmid: 18687777
references.citation: Osteoporos Int. 2013 Apr;24(4):1513-8
references.pmid: 22890364
references.citation: J Clin Invest. 2005 Jun;115(6):1627-35
references.pmid: 15902306
references.citation: Am J Physiol Endocrinol Metab. 2010 Oct;299(4):E601-6
references.pmid: 20606075
references.citation: Genes Dev. 2012 Feb 1;26(3):271-81
references.pmid: 22302939
references.citation: Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3143-8
references.pmid: 22315431
references.citation: Bone. 2012 Feb;50(2):546-52
references.pmid: 21723971
references.citation: J Clin Endocrinol Metab. 2013 Jan;98(1):E98-102
references.pmid: 23150685
references.citation: Cell Metab. 2012 Sep 5;16(3):394-406
references.pmid: 22958922
references.citation: Eur J Endocrinol. 2010 Dec;163(6):863-72
references.pmid: 20826525
references.citation: Endocr Pract. 2012 Sep-Oct;18(5):758-62
references.pmid: 22784851
references.citation: Genes Dev. 2013 Feb 1;27(3):234-50
references.pmid: 23388824